New research has found that beta blockers, a class of drugs used to prevent the progression of heart failure and manage arrhythmias (irregular heart beat) and hypertension (high blood pressure), are underused in heart failure patients who receive implantable cardiac devices. Failure to take beta blockers prior to implanting a cardiac device can affect the patient's overall outcome and survival rate.